XNYS · Healthcare Plans
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$65.11-2.97%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
56/100
Positive
Score components
TickerWhale View
Centene scores 56 out of 100 overall, which we rate positive. Valuation is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%6Weak
- Revenue growth 13.8%
- EPS growth -358.7%
Valuation
25%98Strong
- P/E -6.4
- EV/Sales 0.1
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
#336 by market cap in our coverage · ~61,100 employees · Listed 2001-12-13 · www.centene.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#69 / 139sector rank by TickerWhale Score
TickerWhale Score 56 vs sector average 55.1 (+0.9)
Revenue growth (industry)Top 38%
Gross margin (industry)Top 38%
Return on equity (industry)Top 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
82/100Strong vs universe
Ranks 82nd of 100 covered names on our technical composite — the composite itself scores 65/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Sell
0 buy · 4 sell · 4 neutral of 8 votes
TickerWhale rates CNC's technical setup strong — 82nd percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
3 / 9constructive
- vs 200-day+26.1%
- vs 50-day-0.6%
Momentum
Mixed
- RSI (14)48 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength9· weak trend
- MACD (12,26,9)sell(histogram -0.026)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 5 sell — and carry one vote between them.
Oscillators (7) vote individually: 0 buy · 3 sell · 4 neutral.
Result — 0 buy vs 4 sell of 8 votes = Strong Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-6.4 · TTM loss
- P/S (TTM)0.2
- P/B1.4
- EV/EBITDA—
- EV/Sales0.1
- PEG—
Profitability & returns
- Gross margin21.9%
- Net margin-2.5%
- ROE-23.2%
- Debt/Equity0.71
Growth
- Revenue growth (YoY)13.8%
- EPS growth (YoY)-358.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $32.4B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $194.8B | $163.1B | $154.0B |
| Gross profit | $13.9B | $16.8B | $17.3B |
| Operating income | -$7.6B | $3.2B | $2.9B |
| Net income | -$6.7B | $3.3B | $2.7B |
| EPS (diluted) | $-13.53 | $6.31 | $4.95 |
| Free cash flow | $4.3B | -$490M | $7.3B |
| Cash | $17.9B | $14.1B | $17.2B |
| Total debt | $17.4B | $18.5B | $17.8B |
| Equity | $20.0B | $26.4B | $25.8B |
| Net debt | -$487M | $4.5B | $636M |
| Debt / equity | 0.87 | 0.70 | 0.69 |
| Liabilities / assets | 0.74 | 0.68 | 0.69 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNCCurrentCentene | 56 | 65 | -6.4 | — | 1.4 | 0.1 | $65.11 | -2.97% | +13.8% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.